Lupin Pharmaceuticals Inc., a subsidiary of the Mumbai-based Lupin Limited, has reached a $30 million settlement with Humana Inc. regarding civil antitrust litigation in the United States. This case is part of the larger In re Generic Pharmaceuticals Antitrust Litigation, which involves multiple pharmaceutical companies accused of price-fixing and market allocation in the generic drug sector. Although Lupin denies the allegations, the settlement aims to mitigate ongoing legal costs and uncertainties. The amount has already been reflected in the company's financial statements. In its latest financial report, Lupin announced a 37.46% increase in consolidated net profit, reaching ₹1,175.55 crore for Q3 FY26, compared to ₹855.16 crore in the same quarter the previous year. Despite this positive financial performance, Lupin's stock saw a slight decline of 0.28%, trading at ₹2320 on the Bombay Stock Exchange (BSE).